Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial
Yihong Zhou, Yuanyuan Qin, Xia Liu, Qingxia Zhao, Min Wang, Yuanyuan Chen et al. Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial. // BMC Infectious Diseases. – 2026. – DOI: 10.1186/s12879-026-12987-3. – URL: https://doi.org/10.1186/s12879-026-12987-3
Yihong Zhou, Yuanyuan Qin, Xia Liu, Qingxia Zhao, Min Wang, Yuanyuan Chen, Ying Li, Kun He, Xiaofeng Li, Vijay Harypursat, Dong Xie, & Yaokai Chen (2026). Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-12987-3
Yihong Zhou, et al. “Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial.” BMC Infectious Diseases, 2026. doi:10.1186/s12879-026-12987-3.
@article{Zhou2026,
title = {Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial},
author = {Zhou, Yihong and Qin, Yuanyuan and Liu, Xia and Zhao, Qingxia and Wang, Min and Chen, Yuanyuan and Li, Ying and He, Kun and Li, Xiaofeng and Harypursat, Vijay and Xie, Dong and Chen, Yaokai},
journal = {BMC Infectious Diseases},
year = {2026},
doi = {10.1186/s12879-026-12987-3},
url = {https://doi.org/10.1186/s12879-026-12987-3}
}